Immix Biopharma

IMMXPhase 2

Los Angeles, United StatesFounded 2012immixbio.com

Immix Biopharma is a public company (NASDAQ: IMMX) focused on developing transformative cell therapies for serious diseases, starting with AL Amyloidosis. Its core innovation is the N-GENIUS platform, which produces sterically-optimized CAR-Ts designed to overcome neurotoxicity—the major barrier to CAR-T adoption. The company has achieved key milestones including FDA Breakthrough Therapy Designation for NXC-201, strong Phase 1b/2a clinical results (92% ORR), and recently closed a $100 million underwritten offering to advance its pipeline.

Market Cap

$482.4M

Founded

2012

Focus

NanotechnologySmall Molecules

IMMX · Stock Price

USD 9.11+6.98 (+327.70%)

Historical price data

AI Company Overview

Technology Platform

The N-GENIUS sterically-optimized Cell Therapy Platform with EXPAND technology, designed to produce CAR-T cell therapies with significantly reduced neurotoxicity and cytokine release syndrome (CRS) while maintaining high efficacy.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage	Watch
Imx-110	Solid Tumor, Adult	Phase 1/2
NXC-201 CAR-T	Light Chain (AL) Amyloidosis	Phase 1/2

Funding History

Total raised: $30M

IPO$15MUndisclosedNov 18, 2021

Series A$12MNextech InvestMar 15, 2020

Seed$3MUndisclosedJun 15, 2018

Opportunities

Immix has a first-mover opportunity to establish NXC-201 as the first approved CAR-T therapy for relapsed/refractory AL Amyloidosis, a market with no current approved treatments.

The platform's safety profile also creates a significant expansion opportunity into autoimmune diseases and enables treatment at the 95% of U.S.

medical centers currently unable to administer CAR-Ts, dramatically increasing market access.

Risk Factors

Key risks include clinical trial failure in ongoing Phase 2 studies, regulatory hurdles for a first-in-disease therapy, the complex and costly manufacturing of autologous cell therapies, and the need to educate a broad physician base.

The company remains pre-revenue and may require additional capital.

Competitive Landscape

NXC-201 faces no direct CAR-T competitors in AL Amyloidosis. Its primary differentiation from approved BCMA CAR-Ts (e.g., Abecma, Carvykti) is a significantly improved neurotoxicity profile (8-10x lower), positioning it as a potential best-in-class, safety-first therapy capable of treating more fragile patients and expanding into community care settings.

Publications

Patents

Pipeline